Genzyme (GENZ) and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics
More News related to GENZ
- Genzyme Seeks U.S. Approval for Clolar(R) to Treat Adult AML
- Genzyme and the International Center for Genetic Engineering and Biotechnology Form Collaboration to Advance Treatments for Neglected Diseases
- Myozyme Produced at the 2000 L Bioreactor Scale to Receive Accelerated Approval
- Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- Four Join Board of SAFE-BioPharma Association
More News related to Corporate News
- Raymond James Starts Millicom (MICC) at Strong Buy
- Stifel Nicolaus Starts City National (CYN) at Hold
- Stifel Nicolaus Starts eHealth (Nasdaq: HLTH) with a Buy
- Wasserman & Associates initiates coverage on American Physicians Service Group (AMPH) with a Buy
- Jesup & Lamont Initiates Coverage on AutoZone (AZO) with a Hold.
Genzyme Corp. (Nasdaq: GENZ) and Medicines for Malaria Venture, a not-for-profit virtual R&D organization dedicated to reducing the burden of malaria, announced today a new collaboration with India's Advinus Therapeutics Ltd. The collaboration seeks to develop new, improved treatments for specific patient groups most at risk for malaria, an often fatal infectious disease of developing countries, particularly affecting pregnant women and infants.
The ongoing MMV/Genzyme partnership also includes The Broad Institute of MIT and Harvard. The team has begun to identify promising lead candidates, coming out of its innovative platform for high-throughput screening of several compound libraries. Among the kinds of compounds to be optimized, with the help of Advinus, are those active against key target enzymes that are essential for the survival of the malaria parasite.
Genzyme Corporation operates as a biotechnology company worldwide.
Related Categories
Corporate NewsStocks Mentioned
+2.35Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
